Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glucovance · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Glucovance (metformin HCl/glyburide) | DRUG | - |
| metformin HCl | DRUG | - |
| glyburide | DRUG | - |
Children ages 9-16 years with a diagnosis of type 2 diabetes mellitus who are not adequately controlled with diet and exercise, with or without oral hypoglycemic therapy, and have an HbA1c greater than 6.4%
Glucovance is used for Diabetes Mellitus, Non-Insulin-Dependent, also known as type 2 diabetes. It is a small molecule combination therapy developed by Bristol-Myers Squibb Company. The drug combines metformin HCl and glyburide, two oral agents that help manage blood glucose in patients with type 2 diabetes.
Glucovance is made by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb is the developer of the metformin HCl and glyburide combination product.
Glucovance has been studied in Phase 3 clinical development. The Phase 3 trial NCT00035542 evaluated the safety and efficacy of Glucovance compared to metformin and glyburide in children and adolescents with type 2 diabetes. That trial is now completed.
Glucovance has been evaluated in one completed Phase 3 clinical trial, NCT00035542. The study was titled A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. It was conducted in the United States and enrolled participants aged 9 years and older.